Literature DB >> 20832512

Bisphosphonates in Paget's disease.

Ian R Reid1, D J Hosking.   

Abstract

Paget's disease is the best example of a common high turnover bone disease. A review of the early use of bisphosphonates in the treatment of this condition shows that many of the fundamental therapeutic issues were identified using drugs which by today's standards were far from ideal. Over the succeeding decades there has been a steady increase in potency culminating in the introduction of intravenous zoledronic acid which is capable of inducing long term remissions which were unthinkable when bisphosphonates were first introduced.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20832512     DOI: 10.1016/j.bone.2010.09.002

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  9 in total

1.  Long-term control of Paget's disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a "real world" setting.

Authors:  Yair Liel; Muhammad Abu Tailakh
Journal:  Endocrine       Date:  2018-11-08       Impact factor: 3.633

2.  Effect of alendronate on the progression of periodontitis induced by Porphyromonas gingivalis and Fusobacterium nucleatum: a study in rats.

Authors:  Carmen L Mueller Storrer; Tatiana Miranda Deliberador; Allan Fernando Giovanini; Viviane Crivellaro; João Cesar Zielak; Giuseppe Alexandre Romito
Journal:  Clin Oral Investig       Date:  2016-03-09       Impact factor: 3.573

Review 3.  Drug delivery nanocarriers and recent advances ventured to improve therapeutic efficacy against osteosarcoma: an overview.

Authors:  Sujit Arun Desai; Arehalli Manjappa; Preeti Khulbe
Journal:  J Egypt Natl Canc Inst       Date:  2021-02-08

4.  Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62P394L mouse model of Paget's disease.

Authors:  Anna Daroszewska; Lorraine Rose; Nadine Sarsam; Gemma Charlesworth; Amanda Prior; Kenneth Rose; Stuart H Ralston; Robert J van 't Hof
Journal:  Dis Model Mech       Date:  2018-08-23       Impact factor: 5.758

5.  Engineering of a New Bisphosphonate Monomer and Nanoparticles of Narrow Size Distribution for Antibacterial Applications.

Authors:  Nimrod Tal; Safra Rudnick-Glick; Igor Grinberg; Michal Natan; Ehud Banin; Shlomo Margel
Journal:  ACS Omega       Date:  2018-02-02

Review 6.  A Review on the Molecular Mechanisms of Action of Natural Products in Preventing Bone Diseases.

Authors:  Innocent U Okagu; Timothy P C Ezeorba; Rita N Aguchem; Ikenna C Ohanenye; Emmanuel C Aham; Sunday N Okafor; Carlotta Bollati; Carmen Lammi
Journal:  Int J Mol Sci       Date:  2022-07-30       Impact factor: 6.208

7.  The inhibition of human farnesyl pyrophosphate synthase by nitrogen-containing bisphosphonates. Elucidating the role of active site threonine 201 and tyrosine 204 residues using enzyme mutants.

Authors:  Maria K Tsoumpra; Joao R Muniz; Bobby L Barnett; Aaron A Kwaasi; Ewa S Pilka; Kathryn L Kavanagh; Artem Evdokimov; Richard L Walter; Frank Von Delft; Frank H Ebetino; Udo Oppermann; R Graham G Russell; James E Dunford
Journal:  Bone       Date:  2015-08-28       Impact factor: 4.398

8.  Hydrogen Sulfide and Carbon Monoxide Protect Gastric Mucosa Compromised by Mild Stress Against Alendronate Injury.

Authors:  Marcin Magierowski; Katarzyna Magierowska; Jakub Szmyd; Marcin Surmiak; Zbigniew Sliwowski; Slawomir Kwiecien; Tomasz Brzozowski
Journal:  Dig Dis Sci       Date:  2016-08-19       Impact factor: 3.199

9.  Near IR fluorescent conjugated poly(ethylene glycol)bisphosphonate nanoparticles for in vivo bone targeting in a young mouse model.

Authors:  S Rudnick-Glick; E Corem-Salkmon; I Grinberg; R Yehuda; S Margel
Journal:  J Nanobiotechnology       Date:  2015-11-14       Impact factor: 10.435

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.